Involvement of calpain in the process of Jurkat T cell chemotaxis

Journal of Neuroscience Research

Volumn 87, Issue 3, 2009, Pages 626-635

  Butler, Jonathan T ^a   Samantaray, Supriti ^a   Beeson, Craig C ^a,b   Ray, Swapan K ^c   Banik, Naren L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Calpain; Chemotaxis; EAE MS; T cells

Indexed keywords

CALCIUM; CALPAIN; CALPEPTIN; CHEMOATTRACTANT; FURA 2; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; CALCIUM CELL LEVEL; CELL CULTURE; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE MIGRATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

CALCIUM; CALPAIN; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FURA-2; GLYCOPROTEINS; HUMANS; JURKAT CELLS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 62849093012     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21882     Document Type: Article

References (41)

1. Bach TL, Chen Q-M, Kerr WT, Wang Y, Lian L, Choi JK, Wu D, Kazanietz MG, Koretzky GA, Zigmond S, Abrams CS. 2007. Phospholipase Cβ is critical for T cell chemotaxis. J Immunol 179:2223-2227.
2. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. 1994. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 91:3652-3656.
3. Colvin RA, Campanella GSV, Sun J, Luster AD. 2004. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279:30219-30227.
4. Cope AP, Schulze-Koops H, Aringer M. 2007. The central role of T cells in rheumatoid arthritis. Clin Exp Reumatol 25(5 Suppl 46):S4-S11.
5. Das A, Sribnick EA, Wingrave JM, Del Re AM, Woodward JJ, Appel SH, Baruk NL, Ray SK. 2005. Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J Neurosci Res 81:551-562.
6. Franco SJ, Huttenlocher A. 2005. Regulating cell migration: calpains make the cut. J Cell Sci 118:3829-3838.
7. Frevert CW, Wong VA, Goodman RB, Goodwin R, Martin TR. 1998. Rapid fluorescence-based measurement of neutrophil migration in vitro. J Immunol Methods 213:41-52.
8. Graves MC, Fiala M, Dinglasan LA, Liu NQ, Sayre J, Chiappelli F, van Kooten C, Vinters HV. 2004. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord 5:213-219.
9. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450.
10. Guyton MK, Das A, Matzelle DD, Samantaray S, Azuma M, Inoue J, Ray S, Banik NL. 2006. SJA6017 attenuates immune cell infiltration and neurodegneration in EAE. In: Tabira T, Yamamura T, Kira J, eds. Proceeding of the 8th International Congress of Neuroimmunology. Medimond, Italy p. 37-40.
11. Hassen GW, Feliberti J, Kesner L, Stracher A, Mokhtarian F. 2006. A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 180:135-146.
12. Hickey WF. 1991. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation, Brain Pathol 1:97-105.
13. Huttenlocher A, Palecek SP, Lu Q, Zhang W, Mellgren RL, Lauffenburger DA, Ginsberg NIH, Horwitz AF. 1997. Regulation of cell migration by the calcium-dependent protease calpain. J Biol Chem 272: 32719-32722.
14. Imam SA, Guyton MK, Haque A, Vandenbark A, Tyor WR, Ray SK, Banik NL. 2007. Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol 190:139-145.
15. Janossy J, Ubezio P, Apati A, Magocsi M, Tompa P, Friedrich P. 2004. Calpain as a multi-site regulator of cell cycle. Biochem Pharmacol 67:1513-1521.
16. Jee Y, Yoon WK, Okura Y, Tanuma N, Matsumoto Y. 2002. Upregulation of monocyte chemotactic protem-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 128:49-57.
17. Kleinschnitz C, Meuth S, Stüve O, Kieseier B, Wiendl H. 2007. Multiple sclerosis therapy: an update on recently finished trials. J Neural 254:1473-1490.
18. Koralnik IJ. 2006. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neural 60:162-173.
19. Leloup L, Mazeres G, Daury L, Cottin P, Brustis JJ. 2006. involvement of calpains in growth factor-mediated migration. Int J Biochem Cell Biol 38:2049-2063.
20. Liu X, Harriman JF, Schnellmann R.G. 2002. Cytoprotective properties of novel nonpeptide calpain inhibitors in renal cells. J Pharmacol Exp Ther 302:88-94.
21. Lokuta MA, Nuzzi PA, Huttenlocher A. 2003. Calpain regulates neutrophil chemotaxis. Proc Natl Acad Sc U S A 160:4006-4011.
22. Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivisakk P, Tucky B, Kidd G, Kingsbury GA, Chang A, Fox RJ, Mack M, Sniderman MB, Ravid R, Staugaitis SM, Stins MF, Ransohoff RM. 2006. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129:212-223.
23. McFarland HF, Martin R. 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nat Inummol 8:913-919.
24. Penna D, Muller S, Martinon F, Demotz S, Iwashima M, Valitutti S. 1999. Degradation of ZAP-70 following antigenic stimulation in human T lymphocytes: role of calpain proteolytic pathway. J Immunol 163:50-56.
25. Ransohoff RM. 2007. Natalizumab for multiple sclerosis. N Engl J Med 356:2622-2629.
26. Ray SK, Hogan EL, Banik NL. 2003. Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Rev 42:169-185.
27. Sanders SK, Crean SM, Boxer PA, Kellner D, LaRosa GJ, Hunt SW, III. 2000. Functional differences between monocyte chemotactic protein-1 receptor A and mopocyte chemotactic proptein-1 receptor B expressed in a Jurkat T cell. J-Immunal 165:4877-4883.
28. Schaecher KE, Goust J-M, Banik NL. 2001. The effects of calpain inhibition upon IL-2 and CD25 expression in human peripheral blood mononuclear cells. J Neuroimmunol 119:333-342.
29. Schaecher K, Goust J-M, Banik N. 2004. The effects of calpain inhibition on IkBα degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem Res 29:1443-1451.
30. Shao H, Chou J, Baty CJ, Burke NA, Watkins SC, Stolz DB, Wells A. 2006. Spatial localization of m-calpain to the plasma membrane by Pphosphoinositide biphosphite binding during epidermal growth factor receptor-mediatel activation. Mol Cell Biol 26:5481-5496
31. Shields DC, Tyor WR, Deibler GE, Hogan EL, Banik NL. 1998. Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 95:5768-5772.
32. Shields DC, Schaecler KE, Goust J-M, Banik NL. 1999. Calpain activity and expression are increased in splenic inflammatory cells associated with experimental allergic encephalomyelitis. J Neuroimmunol 99:1-12.
33. Shiraha H, Glading A, Chou J, Jia Z, Wells A. 2002. Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. Mol Cell Biol 22:2716-2727.
34. Swanborg RH. 2001. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol Rev 184:129-135.
35. Vicente-Manzanares M, Webb DJ, Horwitz AR. 2005. Cell migration at a glance. J Cell Sci 118:4917-4919.
36. Waksman BH, Adams RD. 1962. A histologic study of the early lesion in experimental allergic encephalomyelitis in the guinea pig and rabbit. Am J Pathol 41:135-162.
37. Wang KKW. 1990. Developing selective inhibitors of calpain. Trends Pharmacol Sci 11:139-142.
38. Wang KKW, Nath R, Posner A, Raser KJ, Buroker-Kilgore M, Hajimohammadreza I, Probert AW Jr, Marcoux FW, Ye Q, Takano E, Hatanaka M, Maki M, Caner H, Collins JL, Fergus A, Lee KS, Lunney EA, Hays SJ, Yuen P-W. 1996. An α-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci U S A 93:6687-6692.
39. Wilkinson PC. 1998. Assays of leukocyte locomotion and chemotaxis. J Immunol Methods 216:139-153.
40. + lymphocytes: a role for cychn D1 and calpain. Exp Gerontol 39:577-585.
41. Zhivotovsky B, Burgess DH, Vanags DM, Orrenius S. 1997. Involvement of cellular proteolytic machinery in apoptosis. Biochem Biophys Res Commun 230:481-488.